Recipient organisationThe Christie NHS Foundation TrustSource-published name: The Christie NHS Foundation Trust
Funding£7.6M
PeriodMar 2018 — Apr 2022
In plain English
AI plain-English summary
Manchester is building a coordinated system to turn patients’ own cells into living drugs and deliver them to thousands of people, not just a handful. Advanced therapies—treatments that genetically modify or multiply a patient’s cells before infusing them back—have shown remarkable results against some cancers and rare diseases. But each dose is custom-made, the supply chain is fragmented, and the cost and complexity have kept these therapies available to only small numbers of patients in specialised centres. iMATCH, a consortium of two NHS trusts, the University of Manchester, and nine companies, aims to solve the logistical bottlenecks that block scale-up. If successful, the project will create standardised systems for collecting, processing, tracking, and storing patient cells across a population of 3.2 million people. It will also design training programmes for NHS staff, then share them nationally and internationally. The immediate impact is not a new drug but the infrastructure to run larger, safer clinical trials—and eventually to make advanced therapies a routine NHS treatment rather than a rare exception.
View original technical description
"Advance Therapies are a new generation of treatments which use patients' cells as 'drug' to treat a variety of diseases. Although encouraging results have been reported, this technology is complex, expensive and currently only available to small numbers of patients. We have formed the Innovate Manchester Advanced Therapy Centre Hub (iMATCH); this is a group of collaborators who share a vision of working more efficiently together so we can offer Advanced Therapies to more children and adult patients with cancer and non-cancer diseases. iMATCH unites experts from The Christie NHS Foundation Trust and Manchester University NHS Foundation Trust, The University of Manchester and 9 businesses with specific expertise in different aspects of delivering Advanced Therapies. Our 9 commercial partners are; Cellular Therapeutics, Aptusclinical, Chaucer, Datatrial, Formedix, Asymptote, AstraZeneca, Agenus and The Christie Pathology Partnership. iMATCH will resolve the challenges and expand facilities to allow us to design and run larger clinical trials so that we can to treat greater numbers of patients within the NHS, safely and efficiently. We are going to focus on; * Coordinating patient cell collection * Processing and storage of those cells * Developing efficient systems to track samples from the patient, through manufacture and back to the patient * Ensure we have all the information we need, from each patient we treat, to know whether a clinical trial has been a success; this will include long term follow-up of patients These clinical trials are complex and challenging to run; it is important that we provide specific education for our doctors, nurses and the teams that support them. We want to define the education packages needed then offer this training to all Manchester-based partners, then any national and international teams. This will increase the use of Advanced Therapies world-wide. Manchester is an excellent choice for this investment by Innovate UK; we have a large population of 3.2 million people, two substantial hospital sites with existing experience offering these treatments to a variety of patients, a devolved Health Care System and an ability to draw together companies who can help us to overcome the complex challenges. Together we will improve patient outcomes."
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know